Project 523 Begins, 1967

The Cultural Revolution (1966–1976) closed or disrupted universities, laboratories, publications, and careers and subjected intellectuals to political persecution. Project 523 was exceptional because a high-priority, military-supervised task could command people, specimens, field sites, and scarce laboratory resources while much ordinary research was stalled. Describing that protection should not romanticise the political violence around it. ^[2]

Nor was the programme a simple victory of “traditional” over “modern” medicine. Chinese-medicine institutions had employed laboratory-trained scientists alongside textual specialists and practitioners since the 1950s. Project 523 made that mixed institutional culture useful to a state mission: reported remedies could generate leads, but plants still had to be identified, preparations standardised, effects tested, active compounds isolated, and dosage forms manufactured. ^{[1] [2]}

The programme’s urgency also shaped its ethics. In her much later account, Tu wrote that she and colleagues first took the qinghao extract themselves before it was given to patients because China then lacked a formal procedure for such safety evaluation. This retrospective testimony documents the team’s reasoning; self-experimentation and the small early patient series are not equivalents of independent ethics review or a modern controlled trial. ^[3]

1. 23 May 1967: national science and PLA bodies convened the antimalarial collaboration later known by the date code “523.” Its remit included prevention as well as treatment and both synthetic and plant-based routes.^[1]
2. 1969: the national 523 office asked the Academy of Traditional Chinese Medicine’s Institute of Chinese Materia Medica in Beijing to search Chinese medicines. Tu Youyou was appointed to lead its group. Her retrospective account says the group assembled more than 2,000 recorded prescriptions and circulated a 640-item collection, then tested selected preparations rather than treating the compilation itself as proof.^[3]
3. 4 October 1971: after inconsistent earlier results, Tu’s team recorded complete parasite suppression in a rodent-malaria test with sample 191, a neutral, low-temperature ethyl-ether extract of qinghao. Tests in monkeys followed. The “100%” attached to this episode refers to those experimental models, not a claim that a finished drug cured every patient.^[3]
4. 8 March 1972: Tu presented the extract at a national Project 523 meeting in Nanjing. A surviving presentation summary reports 95–100% suppression in rodent and monkey work, evidence that helps distinguish this result from earlier, variable qinghao screens.^[4]
5. August–November 1972: Tu’s group reported treatment of 21 malaria patients in Hainan and nine at Beijing’s No. 302 Hospital, then isolated active crystals from the neutral extract. The uncontrolled series was encouraging within the programme, but its size and design limit what it can establish by current standards.^[3]
6. 1973–1975: groups in Beijing, Yunnan, Shandong, Guangzhou, and the Chinese Academy of Sciences contributed purification, further clinical work, structural analysis, derivatives, and formulation. A failed 1973 tablet trial—traced to tablets that did not disintegrate properly—also shows that isolating an active molecule was not the same as producing a reliable medicine.^[3]
7. 1977–1979: a short, collectively authored Chinese paper announced the new sesquiterpene lactone qinghaosu in 1977. In December 1979, Chinese Medical Journal published the collective English-language report “Antimalaria Studies on Qinghaosu.” It reported rapid clearance of blood-stage parasites in a large accumulated case series, but also acknowledged short-term recurrence and no effect on tissue stages—limits that heroic summaries often omit.^[5]
8. 1980s onward: international meetings, additional trials, derivatives such as artesunate and artemether, manufacturing standards, and combination regimens carried the work beyond Project 523. The 2015 Nobel Prize recognised Tu’s discoveries, while renewed attention also exposed unresolved disagreements about how individual and collective contributions should be narrated.^[4]

Tu’s team revisited a passage in Ge Hong’s fourth-century Zhouhou beiji fang, usually translated as Emergency Prescriptions Kept Up One’s Sleeve. Its instruction to soak qinghao in water and wring out the liquid, rather than boil it, helped prompt experiments with lower-temperature extraction. Altering the solvent, temperature, acidity, plant part, species, and harvest conditions eventually made the antimalarial activity reproducible. ^{[2] [3]}

The passage did not name artemisinin, and its historical fever terminology should not be silently converted into a laboratory-confirmed diagnosis of malaria. Qinghao was also a materia-medica name whose botanical referent and preparation varied. The historically defensible claim is that an old text changed the modern team’s experimental questions—not that a fourth-century author discovered a twentieth-century molecule. ^[2]

Tu’s low-temperature neutral extraction, the 1972 national report, and her institute team’s isolation work are documented, substantive contributions. Project records and later participants’ accounts also identify essential work by other institutes. The 2015 Nobel award was therefore defensible recognition of a key discovery, but it was not a complete personnel history of Project 523. ^[4]

Evidence for the sequence is uneven. The 1979 paper is contemporary and collective, but says little about individual labour. Tu’s Nobel lecture is detailed and connects events to surviving dates, yet it is a first-person reconstruction delivered more than four decades later and after disputes over credit. Historians therefore compare meeting summaries, institute reports, publications, oral histories, and retrospective testimony rather than treating any single commemoration as final. ^{[1] [3] [4]}

Artemisinin’s documented global importance belongs to standardized drugs, derivatives, partner medicines, and health systems—not to an unchanged plant remedy. The World Health Organization currently describes artemisinin-based combination therapies (ACTs) as the mainstay of recommended treatment for Plasmodium falciparum malaria. Combining a rapidly acting artemisinin derivative with a longer-acting partner helps clear remaining parasites; emerging partial resistance makes surveillance and appropriate combination treatment essential. ^[6]

This history is not treatment advice. WHO does not support using non-pharmaceutical Artemisia plant material—teas, tablets, or capsules—to prevent or treat malaria, because plant preparations do not provide the assured dose, quality, or therapeutic partnership of an approved ACT. ^[7]